Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$72,700 | -$135,352 | -$108,501 | -$73,958 |
| Dep. & Amort. | $8,121 | $6,222 | $3,745 | $2,132 |
| Deferred Tax | $0 | $0 | $0 | $17 |
| Stock-Based Comp. | $18,126 | $16,669 | $11,664 | $5,200 |
| Change in WC | $91,397 | $72,466 | -$2,134 | $6,286 |
| Other Non-Cash | -$2,948 | -$3,807 | $2,760 | $960 |
| Operating Cash Flow | $41,996 | -$43,802 | -$92,466 | -$59,363 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,988 | -$19,041 | -$12,911 | -$9,732 |
| Net Acquisitions | $0 | $62 | $109 | $79 |
| Inv. Purchases | -$230,361 | -$103,151 | -$384,417 | $0 |
| Inv. Sales/Matur. | $189,897 | $210,931 | $178,000 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$44,452 | $88,801 | -$219,219 | -$9,653 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $944 | $27,492 | $20,055 | $237,750 |
| Stock Repurch. | -$641 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $98,589 | $0 | $411 | $139,812 |
| Financing Cash Flow | $98,892 | $27,492 | $20,466 | $377,562 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $96,436 | $72,491 | -$291,219 | $308,546 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $132,681 | $60,190 | $351,409 | $42,863 |
| End Cash | $229,117 | $132,681 | $60,190 | $351,409 |
| Free Cash Flow | $38,008 | -$62,843 | -$105,377 | -$69,095 |